Phoenix

Nanotechnologies fundamentally change the current therapies and enable development of novel treatments and diagnostic approaches. The improvements in medical therapies and diagnostics achieved through innovative medical nanoproducts have a significant and direct clinical impact and provide benefits for the patients. Hence, best practices in design and development of such nanoproducts will contribute to societal prosperity and welfare, by providing access to safer and more effective treatments. 

On 3 March 2023, the EU-funded project PHOENIX-OITB, co-organized a stakeholder workshop with the COST action Nano2Clinic and H2020 SENDER project to strengthen relations between industry, R&D&I sector, regulatory agencies, clinics, and patients with the ultimate goal of fostering the clinical translation of nanomedicine from bench to bedside. By promoting scientific exchanges, technological implementation and innovative solutions, the meeting yielded dialogue for rationalizing and focusing research efforts at the EU level in dealing with the challenge of nanomedicine translation for cancer therapies. Several speakers presented on a variety of topics, from best practices in clinical translation of orphan nanodrugs to regulatory aspects in clinical translation of nano-enabled products to theranostic nanomedicine design. The informative event included lively exchanges during Q&As and during the breaks and following dinner. We were happy to welcome nearly 40 attendees in person in beautiful Zagreb!

Take a look at the short recap: